Beta Amyloid PET Imaging for Alzheimer Disease With [18F]-Fluselenamyl

Description

The purpose of this research study is to determine the safety of a radiotracer 18F-Fluselenamyl using positron emission tomography (PET) imaging.

Conditions

Alzheimer Disease

Talk to us

Study Overview

On this page

Study Details

Study overview

The purpose of this research study is to determine the safety of a radiotracer 18F-Fluselenamyl using positron emission tomography (PET) imaging.

Beta Amyloid PET Imaging for Alzheimer Disease: [18F]-Fluselenamyl (Alternative Vehicle) Comparison With [11C]-PIB (FSA-PIB AD)

Beta Amyloid PET Imaging for Alzheimer Disease With [18F]-Fluselenamyl

Condition
Alzheimer Disease
Intervention / Treatment

-

Contacts and Locations

Saint Louis

Washington University School of Medicine, Saint Louis, Missouri, United States, 63110

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Male or Female, any race
  • * Age ≥ 18 years
  • * Healthy volunteers or volunteers with Alzheimer's disease
  • * Has hypersensitivity to 18F-Fluselenamyl or any of its excipients ;
  • * Has hypersensitivity to 11C-PIB or any of its excipients ;
  • * Incapable of providing written informed consent or lacking a legally authorized representative (LAR) to provide informed consent ;
  • * Unwilling or unable to undergo PET scans tracer injections ;
  • * Unwilling or unable to undergo MRI (Aim 2 and Aim 3)
  • * Any condition that, in the Investigator's opinion, could increase the risk to the participant, limit the participant's ability to tolerate the research procedures, or interfere with the collection/analysis of the data (e.g., renal or liver failure, advanced cancer);
  • * Women who are currently pregnant or breast-feeding;
  • * Current or recent (within 12 months prior to screening) participation in research studies involving radioactive agents such that the total research-related radiation dose to the participant in any given year would exceed the limits set forth in the U.S. Code of Federal Regulations (CFR) Title 21 Section 361.1.

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

Yes

Collaborators and Investigators

Washington University School of Medicine,

Tammie Benzinger, MD., PhD, PRINCIPAL_INVESTIGATOR, Washington University School of Medicine

Study Record Dates

2025-11